- Home
- RBOT vs APLT Comparison
RBOT vs APLT Comparison
Compare RBOT & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- APLT
- Stock Information
- Founded
- RBOT 2014
- APLT 2016
- Country
- RBOT United States
- APLT United States
- Employees
- RBOT N/A
- APLT N/A
- Industry
- RBOT Medical Specialities
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- RBOT Health Care
- APLT Health Care
- Exchange
- RBOT Nasdaq
- APLT Nasdaq
- Market Cap
- RBOT 38.3M
- APLT 178.6M
- IPO Year
- RBOT N/A
- APLT 2019
- Fundamental
- Price
- RBOT $5.33
- APLT $1.15
- Analyst Decision
- RBOT Hold
- APLT Buy
- Analyst Count
- RBOT 1
- APLT 5
- Target Price
- RBOT $7.00
- APLT $4.13
- AVG Volume (30 Days)
- RBOT 133.7K
- APLT 3.5M
- Earning Date
- RBOT 11-10-2025
- APLT 11-10-2025
- Dividend Yield
- RBOT N/A
- APLT N/A
- EPS Growth
- RBOT N/A
- APLT N/A
- EPS
- RBOT N/A
- APLT N/A
- Revenue
- RBOT N/A
- APLT $121,000.00
- Revenue This Year
- RBOT N/A
- APLT N/A
- Revenue Next Year
- RBOT N/A
- APLT $5,935.35
- P/E Ratio
- RBOT N/A
- APLT N/A
- Revenue Growth
- RBOT N/A
- APLT N/A
- 52 Week Low
- RBOT $5.00
- APLT $0.30
- 52 Week High
- RBOT $19.00
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- RBOT 40.61
- APLT 50.73
- Support Level
- RBOT $5.14
- APLT $1.08
- Resistance Level
- RBOT $6.19
- APLT $1.31
- Average True Range (ATR)
- RBOT 0.48
- APLT 0.13
- MACD
- RBOT -0.06
- APLT -0.04
- Stochastic Oscillator
- RBOT 8.33
- APLT 15.96
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.